Biotech Stocks AMWL, CUE, ICCC, SRRK, FTH Hit 52-Week Highs

Industry
โดย RTTNews·Read original
Summary · why it matters

Several biotech stocks reached 52-week highs on July 10, 2026, driven by regulatory updates and quarterly results. American Well Corporation hit $10.16, closing at $9.91, after a Nature report validated its SilverCloud platform and it facilitated a DarioHealth insurer agreement, though full-year 2026 revenue is expected at $195 million to $205 million, below 2025's $249.3 million. Cue Biopharma reached $45.50 and announced a roughly $50 million private placement, while advancing CUE-221 in a Phase 2 allergy study and planning an IND for CUE-401. ImmuCell climbed to $11.59 after reporting unaudited second-quarter sales of $7.2 million, an 11.5% year-over-year increase, with $4.9 million from Tri-Shield First Defense. Scholar Rock hit $58.49, up 3.33%, as its BLA for Apitegromab in SMA is under FDA review with a decision expected by September 30, 2026. Faeth Therapeutics touched $36.89, advancing the PIKTOR combination therapy in a Phase 1/2 breast cancer trial with interim data due in 2027 and a Phase 2 endometrial cancer trial with topline data expected in the second half of 2026.

Impact on stocks 5

Biotech & Genomic Medicine▲ · 3 stocks
Cue Biopharma
CUE
▲ PositiveCapitalrelevance

Announced roughly $50 million private placement and advanced CUE-221 in Phase 2 allergy study.

Scholar Rock Holding Corp
SRRK
▲ PositiveRegulationrelevance

BLA for Apitegromab in SMA under FDA review with decision expected by September 30, 2026.

Faeth Therapeutics, Inc.
FTH
▲ PositiveTechnologyrelevance

Advancing PIKTOR combination therapy in Phase 1/2 breast cancer trial with interim data due in 2027 and Phase 2 endometrial cancer trial with topline data expected H2 2026.

Health Care▲ · 1 stocks
ImmuCell Corporation
ICCC
▲ PositiveDemandrelevance

Reported unaudited Q2 sales of $7.2 million, an 11.5% YoY increase, with $4.9 million from Tri-Shield First Defense.

Cloud & Digital Infrastructure▲ · 1 stocks
American Well Corp
AMWL
± MixedDemandrelevance

Nature report validated SilverCloud platform and facilitated DarioHealth insurer agreement, but full-year 2026 revenue expected below 2025.

Theme Impact 4

Related news

Axsome Therapeutics Reports New Clinical Data in Depression and Alzheimer's Agitation

Axsome Therapeutics reported new clinical data in major depressive disorder and Alzheimer's disease agitation at a leading psychiatry congress. The presentations focused on key programs in Axsome's central nervous system pipeline aimed at treating mood and neuropsychiatric symptoms, and management highlighted how the new findings may inform future study designs and regulatory interactions for these indications. The company is advancing multiple late-stage clinical programs, including AXS-05, AXS-12, AXS-14, and several solriamfetol indications, and the fresh congress results give more clinical detail around AXS-05 in depression and Alzheimer's agitation, feeding the thesis that future CNS indications can broaden the revenue mix beyond Auvelity, Sunosi and SYMBRAVO. Axsome, a mid-sized US pharmaceuticals player with a market cap of $11.2b, competes alongside larger CNS-focused drug developers such as Biogen and Eli Lilly and smaller specialists. The same update also stress tests a key risk: management must commercialise several CNS assets at once while running high R&D and SG&A spending, with payer scrutiny and strong rivals in both categories.
AXSM ▲
Biotech & Genomic Medicine
Simply Wall St·7hRead more →
▲2

Novartis Acquires Full Rights to Sironax Brain Delivery Platform

Novartis agreed to acquire full rights to Sironax's proprietary brain delivery platform for neurological disease treatments. The deal gives Novartis control of Sironax's technology designed to transport therapeutics across the blood brain barrier, expanding its toolkit for research into central nervous system disorders where treatment options remain limited. Novartis is a large pharmaceuticals group with a CHF218.8 billion market cap that researches, develops, manufactures, distributes, markets, and sells medicines globally, so gaining access to differentiated delivery technology directly links into its existing focus on complex neurological treatments. The Sironax platform speaks to the same advanced-therapy thesis that underpins Cosentyx's CHMP progress and remibrutinib's Phase 3 data, as Novartis seeks to own hard-to-reach biology where rivals like Roche and Biogen also compete for neurologists' attention. The flip side is that every new modality adds complexity, and recent trial setbacks such as pelacarsen and del-desiran keep development risk front and center, with analysts flagging that stacking capital-intensive projects on top of share buybacks could stretch the balance sheet of a business already carrying a high level of debt.
NOVN.SW ▲
Biotech & Genomic Medicine ▲
Simply Wall St·8hRead more →
2

AbbVie Unveils New VRAYLAR Real-World and Pediatric Safety Data at Psych Congress 2026

AbbVie shared new real-world and pediatric safety data for VRAYLAR in major depressive disorder and bipolar I at Psych Congress 2026. The findings covered routine clinical practice settings, including patients with complex comorbidities and underserved groups, while the pediatric data added information on safety and use in younger patients with mood disorders. AbbVie, a research-focused biopharmaceutical group with a US$466.6b market cap, positions VRAYLAR within a broad portfolio targeting chronic conditions including complex psychiatric disorders. The company said the next concrete checkpoint will be how these data feed into prescribing and label use over the next year, particularly uptake of newly approved low dose VRAYLAR in pediatric and adjunctive MDD settings, trackable in reported prescription trends and segment sales through 2027.
ABBV ▲
Biotech & Genomic Medicine
Simply Wall St·8hRead more →
© 2026 MarketDXNews